IBEX BIOSCIENCES, LLC

Rockville, MD · Founded 2015 · Biotech · Private

Therapeutic antibodies, gene therapies, and regenerative medicine programs

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · ibex.bio

Sector: Biotech
Headquarters: Rockville, MD
Founded: 2015
Latest Form D: $70K, Feb 2025
Total capital: $5.5M

Federal grants: $300K; 1 award · 2017; Rank in peer group#39 of 392
Private capital raised: $5.2M; 4 Form D · last Feb 2025; 20 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 9 pending

Capital timeline

Latest events

Feb 2025Private capital raisedForm D · SEC · 4th filing$70K
Jul 2021Private capital raisedForm D · SEC · 3rd filing$1M
Jan 2020Private capital raisedForm D · SEC · 2nd filing$1.8M
Jan 2020Private capital raisedForm D · SEC · 1st filing$2.4M
Sep 2017Federal grantHealth and Human S · Phase I · Novel Single Chain Antibodies against MIF for Prostate Cancer Therapy$300K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

27months

from IBEX BIOSCIENCES, LLC’s first federal award to its first private round.

First federal award · Sep 2017: Health and Human S · $300K
First Form D · Jan 2020: $2.4M · 1st Form D
Awards before first raise: 1 award

An association in public records, not a cause or a prediction.

Standing among 392 peers

Line = median

Biotech · Molecule

Federal grants#39 · top 10%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Alberto Murat CrociExecutive Officer, DirectorNamed in SEC Form D filings
Michael Joseph KarlinExecutive Officer, DirectorNamed in SEC Form D filings
Roy Joseph FeinsonDirectorNamed in SEC Form D filings
Sylvan Isaac KarlinDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 9

Jul 21, 2022PendingUse Of PCBP1 To Generate Induced Pluripotent Stem Cells While Inhibiting OncogenesisUSPTOApplication 17591309
PendingAntibodies Targeted To CD147USPTOApplication PCTUS2022011969
PendingAntibodies Targeted To CD147USPTOApplication 63135827

Show all 9 patent records

Use Of PCBP1 To Generate Induced Pluripotent Stem Cells While Inhibiting OncogenesisJul 21, 2022 · Application 17591309Pending
Antibodies Targeted To CD147Application PCTUS2022011969Pending
Antibodies Targeted To CD147Application 63135827Pending
Use Of PCBP1 To Generate Induced Pluripotent Stem Cells While Inhibiting OncogenesisApplication PCTUS2020045477Pending
Antibodies Directed To Filamin-a And Therapeutic Uses ThereofApplication PCTUS2019055401Pending
Use Of PCBP1 To Generate Induced Pluripotent Stem Cells While Inhibiting OncogenesisApplication 62883815Pending
Use Of PCBP1 To Treat Hyperproliferative DiseaseApplication PCTUS2019016688Pending
Antibodies Directed To Filamin-a And Therapeutic Uses ThereofApplication 62743169Pending
Use Of PCBP1 To Treat Hyperproliferative DiseaseApplication 62626424Pending

ONCOSYNERGY, INC.Similar federal contract value in Biotech · null in contracts
DATIRIUM LLCSimilar federal contract value in Biotech · null in contracts
TELLUS THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
RESONANT THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
VALITOR, INC.Similar federal contract value in Biotech · null in contracts
ETIRARX, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.